Risks and Benefits of Triple Oral Anti-Thrombotic Therapies After Acute Coronary Syndromes and Percutaneous Coronary Intervention
2015 (English)In: Drug Safety, ISSN 0114-5916, E-ISSN 1179-1942, Vol. 38, no 5, 481-491 p.Article, review/survey (Refereed) Published
The key pathophysiological process underlying symptomatic coronary artery disease, including acute coronary syndromes (ACS), is usually a rupture or an erosion of an atherosclerotic plaque, followed by platelet activation and subsequent thrombus formation. Early clinical trials showed benefit with long-term aspirin treatment, and later-based on large clinical trials-dual anti-platelet therapy (DAPT), initially with clopidogrel, and more recently with prasugrel or ticagrelor, has become the established treatment in the post-ACS setting and after percutaneous coronary intervention (PCI). Treatment with DAPT is recommended for both ST-elevation myocardial infarction and non-ST-elevation ACS, as well as after PCI with stenting, in American and European clinical guidelines. Notwithstanding the benefits observed with DAPT, including third-generation P2Y(12) receptor inhibitors plus aspirin, ACS patients remain at high risk for a recurrent cardiovascular event, suggesting that other treatment strategies, including the addition of a third oral anti-platelet agent or a novel oral anticoagulant (NOAC) to standard DAPT regimens, may provide additional benefit for post-ACS patients and for patients undergoing PCI. Adding a third anti-thrombotic agent to DAPT after an ACS event or a PCI procedure has been shown to have modest benefit in terms of ischemic event reduction, but has consistently been associated with increased bleeding complications. Therefore, the quest to optimize anti-thrombotic therapies post-ACS and post-PCI continues unabated but is tempered by the historical experiences to date that indicate that careful patient and dose selection will be critical features of future randomized trials.
Place, publisher, year, edition, pages
Adis / Springer Verlag (Germany) , 2015. Vol. 38, no 5, 481-491 p.
IdentifiersURN: urn:nbn:se:liu:diva-118035DOI: 10.1007/s40264-015-0286-8ISI: 000353516700005PubMedID: 25829216OAI: oai:DiVA.org:liu-118035DiVA: diva2:813084
Funding Agencies|Astra-Zeneca; Novartis; Merck; Sharp Dome; Sanofi-Aventis; Eli Lilly; Amgen; DaiichiSanko; Janssen Pharmaceuticals; Ferring Pharmaceuticals; ACC; AHA; Familial Hypercholesterolemia Foundation2015-05-212015-05-202016-04-24